Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Collaborative Innovation Center for Cancer Medicine, Beijing, China.
Department of Oncology, Henan Provincial People's Hospital, Zhengzhou, China.
Clin Exp Med. 2020 May;20(2):299-311. doi: 10.1007/s10238-020-00619-2. Epub 2020 Mar 14.
Mucin 4 (MUC4), a type I membrane-bound mucin, blocks apoptosis, promotes invasion, proliferation and migration and causes chemo-resistance in epithelial cancers. However, the expression profiling and clinical implications of MUC4 alternative splicing during cancer pathogenesis, including melanoma, remain obscure. We examined the mRNA expression profiling of MUC4 isoforms in gastrointestinal cancer cell lines, melanoma cell lines, human epidermal melanocyte cells, as well as 138 cases of human melanoma tissues by RT-qPCR. Then we analyzed the relationship of mRNA expression of MUC4 isoforms to clinicopathological characteristics and survival of patients. The dynamic mRNA expression profiling of MUC4 isoforms was found in melanoma. We identified MUC4 isoform f was highly expressed in melanoma cell lines but negative in gastrointestinal cancer cell lines. Clinical analysis based on 138 cases of human melanomas showed that MUC4 isoform d was related with melanoma subtypes (p = 0.028) and TNM stage (p = 0.036). MUC4 isoform e was related with tumor thickness (p = 0.004) and T stage (p = 0.036). The Kaplan-Meier assay showed that the median overall survival (OS) for patients with MUC4 isoform f high expression was significantly shorter than that of patients with low expression (p = 0.024). And the median PFS of the patients with high expression of MUC4 isoform d or e was significantly shorter than that of with low expression (p = 0.012 and 0.035, respectively). Multivariate analysis indicated that high level of MUC4 isoform f was an independent prognostic factor for OS, and MUC4 isoform d was an independent prognostic factor for PFS of patients treated with chemotherapy. In conclusion, our results indicate that the dynamic MUC4 isoforms expressed in melanoma, and MUC4 isoform d and f might be served as a novel prognostic indicator of melanoma patients.
黏蛋白 4(MUC4)是一种 I 型膜结合黏蛋白,可阻止细胞凋亡,促进上皮癌的侵袭、增殖和迁移,并导致化疗耐药。然而,在包括黑色素瘤在内的癌症发病机制中,MUC4 可变剪接的表达谱及其临床意义仍不清楚。我们通过 RT-qPCR 检查了胃肠道癌细胞系、黑色素瘤细胞系、人表皮黑素细胞以及 138 例人黑色素瘤组织中 MUC4 异构体的 mRNA 表达谱。然后,我们分析了 MUC4 异构体的 mRNA 表达与患者临床病理特征和生存的关系。我们发现黑色素瘤中存在 MUC4 异构体的动态 mRNA 表达谱。我们鉴定出 MUC4 异构体 f 在黑色素瘤细胞系中高表达,但在胃肠道癌细胞系中为阴性。基于 138 例人黑色素瘤的临床分析表明,MUC4 异构体 d 与黑色素瘤亚型(p=0.028)和 TNM 分期(p=0.036)有关。MUC4 异构体 e 与肿瘤厚度(p=0.004)和 T 分期(p=0.036)有关。Kaplan-Meier 分析表明,MUC4 异构体 f 高表达患者的中位总生存期(OS)明显短于低表达患者(p=0.024)。而 MUC4 异构体 d 或 e 高表达患者的中位无进展生存期(PFS)明显短于低表达患者(p=0.012 和 0.035)。多变量分析表明,MUC4 异构体 f 高水平是 OS 的独立预后因素,而 MUC4 异构体 d 是化疗患者 PFS 的独立预后因素。总之,我们的研究结果表明,在黑色素瘤中表达的动态 MUC4 异构体,以及 MUC4 异构体 d 和 f,可能成为黑色素瘤患者的一种新的预后指标。